



(43) International Publication Date
2 August 2012 (02.08.2012)

- (51) International Patent Classification:
C07K 14/545 (2006.01) A61P 19/02 (2006.01)
- (21) International Application Number:
PCT/US2012/022583
- (22) International Filing Date:
25 January 2012 (25.01.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|------------------------------|----|
| 61/436,184 | 25 January 2011 (25.01.2011) | US |
| 61/436,178 | 25 January 2011 (25.01.2011) | US |
| 61/493,967 | 6 June 2011 (06.06.2011) | US |
| 61/493,966 | 6 June 2011 (06.06.2011) | US |
| 61/513,472 | 29 July 2011 (29.07.2011) | US |
| 61/513,521 | 29 July 2011 (29.07.2011) | US |

02142 (US). **HOU, Jinzhao** [US/US]; 215 First Street, Suite 400, Cambridge, MA 02142 (US). **KING, Bracken, M.** [US/US]; 215 First Street, Suite 400, Cambridge, MA 02142 (US).

(74) Agent: **HATTON, Allyson, R.**; Lando & Anastasi LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

(71) Applicant (for all designated States except US): **ELEVEN BIOTHERAPEUTICS, INC.** [US/US]; 215 First Street, Suite 400, Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARNES, Thomas, M.** [AU/US]; 215 First Street, Suite 400, Cambridge, MA

[Continued on next page]

(54) Title: CHIMERIC IL-1 RECEPTOR TYPE I AGONISTS AND ANTAGONISTS




FIG. 2

(57) Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive, to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, β strands, and loops from at least two parental cytokines domains.





DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

(88) Date of publication of the international search report:

26 October 2012

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2012/022583

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K14/545 A61P19/02
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07K A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HEIDARY ET AL: "Long-range Coupling Between Separate Docking Sites in Interleukin-1beta", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 353, no. 5, 11 November 2005 (2005-11-11), pages 1187-1198, XP005152798, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2005.08.072 the whole document ----- -/--	1-50

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 28 August 2012	Date of mailing of the international search report 06/09/2012
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Hars, Jesko

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2012/022583

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHARLES A. DINARELLO: "Immunological and Inflammatory Functions of the Interleukin-1 Family", ANNUAL REVIEW OF IMMUNOLOGY, vol. 27, no. 1, 1 April 2009 (2009-04-01), pages 519-550, XP055014922, ISSN: 0732-0582, DOI: 10.1146/annurev.immunol.021908.132612 the whole document	1-50
X	----- HAL M. HOFFMAN ET AL: "Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies", ARTHRITIS & RHEUMATISM, vol. 58, no. 8, 30 July 2008 (2008-07-30), pages 2443-2452, XP055014926, ISSN: 0004-3591, DOI: 10.1002/art.23687 the whole document	18,44-47
X	----- A WINGREN: "Fusion of a Signal Sequence to the Interleukin-1[beta] Gene Directs the Protein from Cytoplasmic Accumulation to Extracellular Release", CELLULAR IMMUNOLOGY, vol. 169, no. 2, 1 May 1996 (1996-05-01), pages 226-237, XP055014943, ISSN: 0008-8749, DOI: 10.1006/cimm.1996.0113 the whole document	18-20, 22,23, 31, 44-46, 48-50
A	----- US 7 700 318 B2 (HUI MIZHOU [US]) 20 April 2010 (2010-04-20) the whole document	1-50
A	----- DEH-MING CHANG ET AL: "Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation", IMMUNOLOGY, vol. 112, no. 4, 1 August 2004 (2004-08-01), pages 643-650, XP055014940, ISSN: 0019-2805, DOI: 10.1111/j.1365-2567.2004.01910.x the whole document	1-50
A	----- WO 98/47921 A1 (SCHERING CORP [US]) 29 October 1998 (1998-10-29) page 16	1-50
	----- -/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2012/022583

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/081091 A2 (SCHEPENS EYE RES INST [US]; DANA REZA [US]; DASTJERDI MOHAMMED [US]; C) 15 July 2010 (2010-07-15) page 8 - page 9 page 28 example 1 claims 5,11,29 sequences 15, 16	1-4,7, 44-50
T	Eric S. Furfine ET AL: "EBI-005: An IL-1 Receptor Inhibitor Designed for the Treatment of Dry Eye Syndrome", 7 May 2012 (2012-05-07), pages 1-1, XP55036406, Retrieved from the Internet: URL: http://www.elevenbio.com/pdf/Eleven_poster_042312_lowres.pdf [retrieved on 2012-08-27] the whole document	
E	WO 2012/016203 A1 (ELEVEN BIOTHERAPEUTICS INC [US]; BARNES THOMAS M [US]; HOU JINZHAO [US]) 2 February 2012 (2012-02-02) the whole document	1-50
A	DATABASE UniProt [Online] 13 July 2010 (2010-07-13), anonymous: "IL1F5_HUMAN", XP002682422, retrieved from www.uniprot.org Database accession no. Q9UBH0 the whole document	1-50
X	DATABASE UniProt [Online] 13 July 2010 (2010-07-13), anonymous: "IL1RA_HUMAN", XP002682423, retrieved from www.uniprot.org the whole document	1-4,7
X	DATABASE UniProt [Online] 23 July 2010 (2010-07-23), anonymous: "IL1RA_MOUSE", XP002682424, retrieved from www.uniprot.org Database accession no. P25085 the whole document	1-4,7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2012/022583

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
US 7700318	B2	20-04-2010	EP 1781684 A2 US 2007082379 A1 WO 2005021578 A2	09-05-2007 12-04-2007 10-03-2005
WO 9847921	A1	29-10-1998	AU 7103198 A CA 2287254 A1 EP 0977779 A1 JP 2002501496 A WO 9847921 A1	13-11-1998 29-10-1998 09-02-2000 15-01-2002 29-10-1998
WO 2010081091	A2	15-07-2010	AU 2010203425 A1 CA 2749537 A1 EP 2385839 A2 JP 2012515164 A US 2010183587 A1 WO 2010081091 A2	28-07-2011 15-07-2010 16-11-2011 05-07-2012 22-07-2010 15-07-2010
WO 2012016203	A1	02-02-2012	NONE	